Expressions of IMP3 in cervical squamous cell carcinoma before and after the therapy of radiation and chemotherapy

Abstract

Abstract:ObjectiveTo discuss the expressions and clinicopathologic significances of insulinlike growth factor Ⅱ mRNA binding protein 3 (IMP3) in squamous intraepithelial lesion (SIL) and cervical squamous cell carcinoma (CSCC) before and after the therapy of radiation and chemotherapy. MethodsThe expressions of IMP3 in 80 cases of CSCC, 90 cases of SIL (60 cases of HSIL, 30 cases of LSIL) and 30 cases of cervicitis were detected by immunobistochemistry. The relations between IMP3 and clinicopathological characteristics of CSCC were analyzed. ResultsThe expression rates of IMP3 in CSCC, HSIL, LSIL and cervicitis were 86.3%(69/80), 78.3%(47/60), 33.3%(10/30) and 0(0/30), and the difference among the four groups was statistically signicant (χ2=87.01, P＜0.01). The positive expression rate of IMP3 declined by radiation or chemotherapy (60.0% vs. 85.0%, χ2=5.79, P=0.013). The expression of IMP3 was related with lymph node metastasis (χ2=3.97, P=0.046), differentiated degree (χ2=5.95, P=0.018), clinical stage (χ2=5.82, P=0.016) and invasion depth (χ2=5.73, P=0.017). There was nothing to do with age (χ2=0.11, P=0.745). ConclusionIMP3 expresses excessively in CSCC, and is associated with pathological grade and invasion progress. Radiochemotherapy can reduce the expression of IMP3.

Key words:Uterine cervical neoplasms,Cervical intraepithelial neoplasia,Immunohistochemistry,Radiotherapy,Drug therapy,Insulinlike growth factor Ⅱ mRNA binding protein 3

Nie Jia, Wu Ning, Zhang Lixia, Huang Yifan, Liu Jun. Expressions of IMP3 in cervical squamous cell carcinoma before and after the therapy of radiation and chemotherapy[J]. Journal of International Oncology, 2016, 43(10): 744-747.

References

［1］ Gage JC, Katki HA, Schiffman M, et al. Agestratified 5year risks of cervical precancer among women with enrollment and newly detected HPV infection［J］. Int J Cancer, 2015, 136(7): 1665-1671. DOI: 10.1002/ijc.29143. ［2］ Yisraeli JK. VICKZ proteins: a multitalented family of regulatory RNAbinding proteins［J］. Biol Cell, 2005, 97(1): 87-96. DOI: 10.1042/BC20040151. ［3］ Samanta S, Sharma VM, Khan A, et al. Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triplenegative breast cancer［J］. Oncogene, 2012, 31(44): 4689-4697. DOI: 10.1038/onc.2011.620. ［4］沈丹华. 解读第4版WHO(2014)女性生殖系统肿瘤分类中宫颈癌前期病变的命名及分级变化［J］. 诊断病理学杂志, 2015, 22(3): 129-132. DOI: 10.3969/j.issn.10078096.2015.03.001. ［5］ Wei Q, Fu B, Liu J, et al. Combined detection of p16(INK4a) and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis［J］. Int J Clin Exp Pathol, 2013, 6(8): 1549-1557. ［6］ Mathew J, Hines JE, Obafunwa JO, et al. CD44 is expressed in hepatocellular carcinomas showing vascular invasion［J］. J Pathol, 1996, 179(1): 74-79. DOI: 10.1002/(SICI)10969896(199605)179:1<74::AIDPATH531>3.0.CO;2E. ［7］ MüellerPillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KHdomain containing protein［J］. Oncogene, 1997, 14(22): 2729-2733. DOI: 10.1038/sj.onc.1201110. ［8］ MuellerPillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis［J］. Mech Dev, 1999, 88(1): 95-99. ［9］ Wang Y, Li L, Wang Y, et al. IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis［J］. J Exp Clin Cancer Res, 2014, 33(1): 60. DOI: 10.1186/s1304601400602. ［10］ Del Gobbo A, Vaira V, Guerini Rocco E, et al. The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung［J］. J Thorac Oncol, 2014, 9(11): 1656-1661. DOI: 10.1097/JTO.0000000000000316. ［11］ Kazeminezhad B, Mirafsharieh SA, Dinyari K, et al. Usefulness of insulinlike growth factor Ⅱ mRNAbinding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases［J］. Turk J Gastroenterol, 2014, 25(3): 253-256. DOI: 10.5152/tjg.2014.5454. ［12］ Gao Y, Yang M, Jiang Z, et al. IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma［J］. Hum Pathol, 2014, 45(6): 1184-1191. DOI: 10.1016/j.humpath.2014.01.016. ［13］魏颖颖, 李劼, 王博, 等. 宫颈重度鳞状上皮内病变和宫颈癌组织中人乳头瘤病毒感染及基因分型的研究［J］. 实用妇产科杂志, 2010, 26(7): 507-509. DOI: 10.3969/j.issn.10036946.2010.07.013. ［14］ Lu D, Yang X, Jiang NY, et al. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer［J］. Am J Surg Pathol, 2011, 35(11): 1638-1645. DOI: 10.1097/PAS.0b013e31823272d4.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[7]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[8]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[11]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[12]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[15]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association.Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version）[J]. Journal of International Oncology, 2023, 50(4): 193-201.